2023

10/05/2023

Proteomics International & Sonic Healthcare USA sign exclusive licence agreement

05/05/2023

New diagnostic blood test showcased at world’s premier endometriosis conference

26/04/2023

Clinical Advisory Board expanded to support PromarkerD USA and global rollout

24/03/2023

New blood test for Endometriosis offers improved early screening

17/03/2023

PromarkerD Application for Australian Medicare Benefits Schedule Listing & Investor Webinar

01/03/2023

US update: PromarkerD licensing negotiations

15/02/2023

Distribution agreement for PromarkerD in Britain extended

03/01/2023

CPT PLA Reimbursement Code Approved in US for PromarkerD

2022

14/12/2022

UK NICE publishes Medtech Innovation Briefing on PromarkerD

11/11/2022

PromarkerD patent granted in Hong Kong

03/11/2022

Proteomics International to present at the Emerging ASX Gems Conference

20/10/2022

Precision diagnostics facility receives $2m funding boost

17/10/2022

Proteomics receives $1.7 million in R&D tax incentive

27/09/2022

New Oesophageal Cancer Diagnostic shows strong performance

29/08/2022

OxiDx launched to maximise oxidative stress technology

15/08/2022

Proteomics International raises $8m in highly successful Placement

09/08/2022

Proteomics International signs binding letter of intent with Sonic Healthcare USA to take PromarkerD into the US market

02/08/2022

Clinical Utility Study demonstrates PromarkerD test benefits

01/08/2022

Potential breakthrough blood test able to detect people with endometriosis

25/07/2022

European PromarkerD patents expanded beyond diabetes

30/06/2022

Promarker™ pipeline – Endometriosis update Diagnostic readout positive: Study expanded

21/06/2022

Proteomics International secures exclusive licence to oesophageal cancer biomarkers

16/06/2022

PromarkerD manufacturing tech-transfer completed – Successful production of components for over 50,000 tests

06/06/2022

Study shows PromarkerD ability to also predict late-stage kidney decline in type-2 diabetes patients

02/06/2022

PromarkerD registration submitted to the TGA

12/05/2022

Proteomics International awarded $400,000 to support manufacturing capability in Australia

12/04/2022

New Clinical Advisory Board for PromarkerD global rollout

24/03/2022

PromarkerD patent granted in India

22/02/2022

PromarkerD completes ‘pre-assessment’ for Medicare rebate

07/02/2022

Novel biomarkers identified for Asthma and COPD

04/02/2022

Unique panel of biomarkers identified for oesophageal cancer

2021

16/12/2021

Proteomics secures major pharmacokinetic testing contract

24/11/2021

FDA advises regulatory pathway for PromarkerD in US

23/11/2021

PromarkerD distribution network expands to Britain

16/11/2021

New Directors appointed to Company Board

05/11/2021

PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline

03/11/2021

Proteomics International awarded $100,000 manufacturing funding

12/08/2021

Proteomics International contracts Biotem to manufacture PromarkerD test kits

11/08/2021

Diabetes treatment lowers PromarkerD risk score: Results presented at Australasian Diabetes Congress

04/08/2021

Proteomics to collaborate to validate test for endometriosis

22/07/2021

Proteomics engages Abcam to manufacture PromarkerD reagents

16/07/2021

Diabetes treatment lowers PromarkerD risk score: Results to be presented at Australasian Diabetes Conference

28/06/2021

World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years

10/06/2021

CCO and CFO appointed to bolster executive team

18/05/2021

Proteomics secures major analytical services contract

13/05/2021

Study demonstrates major economic health benefit of PromarkerD – PromarkerD reimbursement update

29/04/2021

Proteomics International files US FDA 513(g) regulatory submission

23/04/2021

Proteomics International achieves ISO 13485 certification

08/02/2021

Proteomics International seeks FDA approval for PromarkerD

2020

12/11/2020

Middle East is next market for PromarkerD immunoassay test

05/11/2020

PromarkerD clinical assay performance results published

23/10/2020

Proteomics International raises $6m in heavily oversubscribed Placement

16/10/2020

First distribution agreement for PromarkerD immunoassay

12/10/2020

PromarkerD international validation study results published

09/10/2020

Partnership with QIMR Berghofer targets oesophageal cancer

27/07/2020

PromarkerD Intellectual Property portfolio expands

15/06/2020

Big pharma clinical study validates PromarkerD kidney test

25/05/2020

Proteomics International receives COVID-19 research grants

16/04/2020

CE Mark for PromarkerD Immunoassay Kit

07/04/2020

Diagnostics R&D expanded: the Promarker™ Pipeline

31/03/2020

Proteomics International expands study with US big pharma

23/03/2020

Proteomics International to patent biomarkers for diagnosis of endometriosis

23/03/2020

WA company takes further step towards blood test for endometriosis

10/02/2020

PromarkerD presented at Australasian Proteomics conference

14/01/2020

CE Mark for PromarkerD Hub predictive software for DKD

2019

26/11/2019

Cutting-edge Protein Biomarker Analysis Facility for Western Australia

15/11/2019

Proteomics International raises $3m in heavily oversubscribed Placement

12/11/2019

CE Mark for predictive test for diabetic kidney disease

29/10/2019

Proteomics receives $1.1 million in R&D tax incentive

17/09/2019

PromarkerD IVD successfully developed and validated

13/09/2019

PromarkerD showcased at EASD

13/09/2019

PromarkerD launched in Spain

12/09/2019

PromarkerD test ready for launch in Europe

10/09/2019

Proteomics International showcased Promarker™ platform at HUPO 2019

10/09/2019

PromarkerD latest results published in peer reviewed journal

29/07/2019

PromarkerD secures TGA approval for software IVD and Indonesian patent

26/07/2019

Proteomics secures contracts for pharmacokinetic analysis

13/06/2019

PIQ Investor Presentation – 121 Tech Investment Hong Kong

07/06/2019

PromarkerD showcased at American Diabetes Association conference 2019

03/06/2019

Proteomics showcased PromarkerD at BIO Convention

22/02/2019

US patent for identifying drugs for abnormal kidney function

24/01/2019

PromarkerD US market update

2018

26/11/2018

Proteomics signs PromarkerD agreement with US big pharma

09/11/2018

PromarkerD kit version complete – Commercial release imminent

24/10/2018

Diabetic kidney disease test enters Europe & Export Award

17/10/2018

Proteomics receives $834k in R&D Tax Incentive

05/10/2018

Proteomics receives $928k from sale of shareholding in CPR

19/09/2018

Proteomics & Atturos partner to target diagnostics in Europe

12/09/2018

Proteomics to receive $928k from sale of shareholding in CPR

23/08/2018

Diagnostics Update – the Promarker pipeline

17/07/2018

Proteomics secures major contract – nears cash flow positive

22/06/2018

Proteomics at ADA Diabetes Conference

20/06/2018

Proteomics signs deal with Patia for PromarkerD in Mexico

29/05/2018

Proteomics International signs deal to launch PromarkerD test for diabetic kidney disease in USA

19/04/2018

Europe PromarkerD patent granted for diabetic kidney disease

06/04/2018

Conversion of 90% of Proteomics Options raises of $3m

07/03/2018

Proteomics launches PromarkerD

02/02/2018

Strategic alliance and investment in CPR Pharma Services

29/01/2018

PromarkerD diabetic kidney disease patent granted in Japan

2017

14/12/2017

Proteomics and Dimerix partner to improve the treatment of kidney disease